Kyverna Therapeutics: Immune Reset Is Clinically Validated, Market Ignores Potential
Source: SeekingAlpha
2025-11-14 02:24:24 ET
Editor's note: Seeking Alpha is proud to welcome Holger Kujath as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access. Click here to find out more » ...
Read the full article on Seeking Alpha
For further details see:
Kyverna Therapeutics: Immune Reset Is Clinically Validated, Market Ignores Potential
Cabaletta Bio Inc.
NASDAQ: CABA
CABA Trading
-2.29% G/L:
$3.1218 Last:
770,242 Volume:
$3.11 Open:
CABA Latest News
February 24, 2026 08:00:00 am
Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference
February 05, 2026 08:00:00 am
Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
November 10, 2025 07:30:00 am
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
CABA Stock Data
$250,770,856
85,435,369
1.33%
21
N/A
Biotechnology & Life Sciences
Healthcare
US
Philadelphia
